Geron (GERN) Liabilities and Shareholders Equity (2010 - 2026)
Geron (GERN) posted Liabilities and Shareholders Equity of $534.1 million for Q1 2026, down 6.38% sequentially from $570.5 million in Q4 2025, and down 5.04% YoY from $562.4 million in Q1 2025.
Geron (GERN) Liabilities and Shareholders Equity (2010 - 2026) Analysis & Trends
Geron has reported Liabilities and Shareholders Equity for 17 years, with the latest figure at $534.1 million in Q1 2026.
- Quarterly Liabilities and Shareholders Equity fell 5.04% year-over-year to $534.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.2 billion (up 8.62% YoY) and the FY2025 annual result came in at $570.5 million, down 3.91% from the prior year.
- Liabilities and Shareholders Equity fell to $534.1 million in Q1 2026 per GERN's latest filing, from $570.5 million in the prior quarter.
- Over five years, Liabilities and Shareholders Equity peaked at $593.8 million in Q4 2024 and troughed at $190.6 million in Q4 2022.
- A 5-year average of $427.5 million and a median of $445.0 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
- The sharpest annual moves came in 2022 and 2023: Liabilities and Shareholders Equity declined 23.27% in 2022, then jumped 114.13% in 2023.
- Over 5 years, Liabilities and Shareholders Equity stood at $190.6 million in 2022, then jumped by 106.78% to $394.1 million in 2023, then soared by 50.68% to $593.8 million in 2024, then decreased by 3.91% to $570.5 million in 2025, then dropped by 6.38% to $534.1 million in 2026.
- According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $534.1 million, $570.5 million, and $567.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Geron | 1.02 Mn | -299.83 Mn | - | 519.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 519.01 Mn |
| Mar 31, 2026 | 534.12 Mn |
| Dec 31, 2025 | 570.54 Mn |
| Sep 30, 2025 | 567.38 Mn |
| Jun 30, 2025 | 555.20 Mn |
| Mar 31, 2025 | 562.45 Mn |
| Dec 31, 2024 | 593.78 Mn |
| Sep 30, 2024 | 444.95 Mn |
| Jun 30, 2024 | 449.40 Mn |
| Mar 31, 2024 | 482.07 Mn |
| Dec 31, 2023 | 394.08 Mn |
| Sep 30, 2023 | 413.02 Mn |
| Jun 30, 2023 | 415.30 Mn |
| Mar 31, 2023 | 424.88 Mn |
| Dec 31, 2022 | 190.58 Mn |
| Sep 30, 2022 | 232.61 Mn |
| Jun 30, 2022 | 238.16 Mn |
| Mar 31, 2022 | 198.42 Mn |
| Dec 31, 2021 | 226.03 Mn |
| Sep 30, 2021 | 229.10 Mn |